Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: The primers of RT-PCR assays

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques:

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: Top 10 nodes in the network ranked by degree

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques:

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: Molecular docking scores of celastrol with the target proteins (kcal/mol)

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques:

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: Molecular docking data indicated that the binding capacity of celastrol with PTC was significant in the key targets of MMP9 (A), JUN (B), ICAM1 (C), and VCAM1 (D). PTC, papillary thyroid carcinoma.

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques: Binding Assay

Journal: Annals of Translational Medicine

Article Title: The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

doi: 10.21037/atm-21-1854

Figure Lengend Snippet: The differentially expressed of four core proteins in BCPAP cell line after 24 hrs of celastrol treatment. (A) qRT-PCR was used to detect the MMP9, JUN, ICAM1, VCAM1 expression with or without celastrol treatment. (B) Western blotting analyses of MMP9, JUN, ICAM1, VCAM1 expression with or without celastrol treatment. **, P<0.01; ***, P<0.001. Data are expressed as means ± SD.

Article Snippet: The primary antibodies used for the western blot were MMP9 (BOSTER, PB9669; 1:1,000), JUN (BOSTER, BM4168; 1:1,000), ICAM1 (BOSTER, PB9018; 1:1,000), VCAM1 (BOSTER, A01199; 1:1,000) and GAPDH (Cell Signaling Technology, 5174; 1:40,000).

Techniques: Quantitative RT-PCR, Expressing, Western Blot

Journal: Frontiers in Immunology

Article Title: A human 3D immune competent full-thickness skin model mimicking dermal dendritic cell activation

doi: 10.3389/fimmu.2023.1276151

Figure Lengend Snippet: Upon exposure to inflammatory stimuli such as LPS, or sensitizing chemicals such as 1 chloro-2,4-dinitrobenzene (DNCB) or nickel sulfate (NiSO 4 ), keratinocytes start to secrete inflammatory cytokines such as IL-1, TNF-α and IL-18. Subsequently cutaneous dendritic cells such as Langerhans cells and dermal dendritic cells become activated and start to phagocytose haptens or exogenous particles, which is accompanied by cell maturation and the upregulation of CD54 and CD86. Finally, DCs migrate to draining lymph nodes to present the processed antigen in order to activate CD4 + T cells. Created with BioRender.com .

Article Snippet: For staining the cells were incubated in Automacs Running Buffer with the following antibodies (1:50): REA Control (S)-VioGreen (Miltenyi, #130-113-444), REA Control (S)-PE (Miltenyi, #130-113-438), REA Control (S)-APC (Miltenyi, #130-113-434); REA Control (S)-PE-Vio770, (Miltenyi, #130-113-440); CD54-APC (Miltenyi, #130-121-342); CD86-APC (Miltenyi, #130-116-161), CD14-VioGreen (Miltenyi, #130-110-525), CD11c-APC (Miltenyi, #130-113-584) for 10 minutes in the dark.

Techniques:

Journal: Frontiers in Immunology

Article Title: A human 3D immune competent full-thickness skin model mimicking dermal dendritic cell activation

doi: 10.3389/fimmu.2023.1276151

Figure Lengend Snippet: Surface marker expression of CD54 and CD86 (depicted as fold of induction of the percentage of all positive cells) after (A) pre-treatment of THP-1-derived iDCs and (B) topical treatment of the immune competent skin model with dexamethasone for 1 h, followed by NiSO 4 treatment for 23 h. Results were depicted as fold of induction compared to the solvent control [0.3% DMSO]. (C–E) Cytokine secretion of iDCs after 1 h dexamethasone pre-treatment, followed by 23 h of NiSO 4 exposure. Error bars indicate the standard errors of the mean (n = 3 independent experiments for (A, C) and n=4 independent experiments for (B) with *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤ 0.0001).

Article Snippet: For staining the cells were incubated in Automacs Running Buffer with the following antibodies (1:50): REA Control (S)-VioGreen (Miltenyi, #130-113-444), REA Control (S)-PE (Miltenyi, #130-113-438), REA Control (S)-APC (Miltenyi, #130-113-434); REA Control (S)-PE-Vio770, (Miltenyi, #130-113-440); CD54-APC (Miltenyi, #130-121-342); CD86-APC (Miltenyi, #130-116-161), CD14-VioGreen (Miltenyi, #130-110-525), CD11c-APC (Miltenyi, #130-113-584) for 10 minutes in the dark.

Techniques: Marker, Expressing, Derivative Assay, Solvent, Control

Journal: International Journal of Molecular Sciences

Article Title: Heme Oxygenase Protects against Placental Vascular Inflammation and Abortion by the Alarmin Heme in Mice

doi: 10.3390/ijms21155385

Figure Lengend Snippet: Primary antibodies used for immunohistochemical staining for IL-1β, ICAM-1, F4/80 and HO-1. Source and used concentrations of the antibodies are described.

Article Snippet: CD54 , ICAM-1 , 0.34 , Proteintech via Sanbio, Uden, The Netherlands.

Techniques: Immunohistochemical staining, Staining, Concentration Assay